Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

1 Jun 2000

Abstract excerpt

Rituximab (IDEC-C2B8, Mabthera(R)) is a chimeric (human-mouse) monoclonal antibody (MoAb) against the B-cell specific CD20-antigen. It has been used for the clinical treatment of non-Hodgkin's lymphomas, but variable clinical results suggest that some lymphoma cells remain resistant. In the present study we have evaluated the relative efficiencies of humoral and cell-mediated effector mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10849376
DOI: 10.1046/j.1365-3083.2000.00745.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsPMID 10849376Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity Read ↗

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenSemantic proximity Read ↗

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.Semantic proximity Read ↗

High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.Semantic proximity Read ↗

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancerSemantic proximity Read ↗

Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity Read ↗

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasSemantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.